Puberty blockers should remain a treatment option for trans and gender-diverse people but more scrutiny of their use is needed, new draft guidelines show.
The National Health and Medical Research Council published interim advice on Monday for treating children whose gender is different from their sex recorded at birth - known as gender incongruence.